There is one clinical trial.
This study will be conducted in type 2 diabetic patient's to evaluate the if there is a different response of serum lipids after a standard meal (rich in saturated fatty acids) in patients who have the presence of a genetic alteration. This alteration that will be evaluated is a polymorphism, change of an amino acid in the gene of FABP2. This gene that can influence the absorption of lipids in the intestine and subjects who have the altered genotype (presence of T allele) can have an abnormal lipid profile as compared to subjects without this genotype.
FABP2 Ala54Thr Genotype Influences the Postprandial Serum Fatty Acids Profile in Type 2 Diabetic Patients. --- Ala54Thr ---
Inclusion Criteria: - Type 2 diabetes - homozygote to FABP2 polymorphism:TT or AA Exclusion Criteria: - age >75 years - glomerular filtration rate <30ml min-1 - with unstable angina or possible infarct or stroke in the last year Inclusion Criteria: - Type 2 diabetes - homozygote to FABP2 polymorphism:TT or AA Exclusion Criteria: - age >75 years - glomerular filtration rate <30ml min-1 - with unstable angina or possible infarct or stroke in the last year Dyslipidemia Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Dyslipidemias Background: The presence of Ala54Thr polymorphism of intestinal fatty acid-binding protein 2 gene (FABP2) might influence the intestinal absorption of dietary fatty acids (FAs) and has been associated with diabetic nephropathy. --- Ala54Thr ---
Conclusion: The presence of the T allele of Ala54Thr polymorphism of FABP2 gene in type 2 diabetic patients increases absorption of dietary FAs, including the trans-unsaturated FAs, and this might turns these patients more susceptible to the effect of diet composition. --- Ala54Thr ---